Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 56

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 56
---
 and the investors named therein purchased, in a private placement (the “Private
Placement”): 6,250 shares of the Series D Preferred Stock for aggregate proceeds of approximately $5 million, paid through
the transfer of certain Transfer Shares (as defined in the Securities Purchase Agreement) in lieu of cash. The date of the first closing
is referred to as the “First Closing Date.” Each additional closing of the Private Placement is at the option of the investors
upon notice to the Company and subject to satisfaction of customary closing conditions. On April 22, 2025, the Company filed the Certificate
of Designations of Rights and Preferences of the Series D Preferred Stock (the “Certificate of Designations”) for the purpose
of designating and establishing the Company’s Series D Preferred Stock. With respect to dividend rights and rights on liquidation,
winding-up and dissolution, the Company’s Series D Convertible Preferred Stock shall rank (a) junior to the Senior Preferred Stock,
(b) on parity with the Company’s Series C Preferred Stock and (c) senior to the Company’s Series A and Series B Preferred
Stock.

29

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion
and Analysis of Financial Condition and Results of Operations provides information that CERo Therapeutics Holdings, Inc. (“the Company”)
management believes is relevant to an assessment and understanding of its results of operations and financial condition. The discussion
should be read together with (i) the Company’s unaudited condensed consolidated financial statements and related notes that are
presented above and (ii) the Company’s audited consolidated financial statements and related notes and management’s discussion and
analysis of financial condition and results of operations included in the Company’s Annual Report on Form 10-K for the year ended December
31, 2024 filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2025. This Management’s Discussion
and Analysis of Financial Condition and Results of Operations may contain forward-looking statements based upon current expectations that
involve risks and uncertainties. Actual results may differ materially from those anticipated in these forward-looking statements resulting
from various factors. Please see “Cautionary Note Regarding Forward Looking Statements” and “Risk Factors” in
the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the subsequent Quarterly Report on Form 10-Q as
filed